Adverse Effects of Mineralocorticoid Receptor Antagonist Administration

Current Pharmaceutical Design
Manolis S KallistratosAthanasios J Manolis

Abstract

Mineralocorticoid receptor antagonists consist of a class of drugs with pleiotropic beneficial effects in several cardiovascular diseases. However, physicians frequently overlook their use due to the adverse effects of such agents. To determine the adverse effects of mineralocorticoid receptor antagonists and to suggest clinically meaningful options. We present data on the two most administered agents of this class: spironolactone and eplerenone. We conducted an in-depth review of the existing international literature to draft a mini review about the mineralocorticoid receptor antagonists-related side effects. Mineralocorticoid receptor antagonists are associated with increased risk of hyperkalemia and acute deterioration of renal function. Of note, these adverse effects are dose-dependent, more common during the initial period of treatment, and are usually reversed after the withdrawal of therapy. Sex-related adverse events are noted mainly in spironolactone while switching to eplerenone could attenuate those. Mineralocorticoid receptor antagonists therapy is significantly limited due to their side effects. The development of novel non-steroidal mineralocorticoid receptor antagonists could substantially widen the use of such a...Continue Reading

References

Feb 1, 1978·The Journal of Clinical Endocrinology and Metabolism·S M RifkaD L Loriaux
Oct 1, 1978·Clinical Pharmacology and Therapeutics·D H HuffmanD L Azarnoff
Aug 1, 1977·The Journal of Clinical Endocrinology and Metabolism·R Caminos-TorresP J Snyder
Oct 1, 1977·Annals of Internal Medicine·L I RoseG H Williams
Jun 1, 1975·Clinical Obstetrics and Gynecology·R P Dickey, S C Stone
Jan 1, 1989·Journal of Steroid Biochemistry·M de GasparoJ Ménard
Oct 1, 1987·The American Journal of Cardiology·X JeunemaitreJ Menard
May 1, 1995·American Journal of Obstetrics and Gynecology·T D Groves, B Corenblum
Feb 18, 1993·The New England Journal of Medicine·G D Braunstein
Jan 1, 1996·American Journal of Obstetrics and Gynecology·J RigóZ Papp
Jan 29, 1999·Physiological Reviews·B Swynghedauw
Sep 8, 2000·American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation·G L BakrisJ Sowers
Jan 5, 2002·The Journal of Obstetrics and Gynaecology Research·T NohiraM Yoshida
Apr 2, 2003·The New England Journal of Medicine·Bertram PittUNKNOWN Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study Investigators
May 12, 2004·Molecular and Cellular Endocrinology·Susan M Garthwaite, Ellen G McMahon
Nov 23, 2006·Journal of the American College of Cardiology·Ravi G AssomullDudley J Pennell
Aug 19, 2007·Clinical Journal of the American Society of Nephrology : CJASN·Murray EpsteinBruce Beckerman
Mar 4, 2008·Expert Opinion on Pharmacotherapy·Asterios KaragiannisDimitri P Mikhailidis
Apr 12, 2008·Clinical Cardiology·Allan StruthersGordon H Williams
Aug 12, 2008·International Journal of Cardiology·A Brent AlperAli Ahmed
Dec 11, 2008·European Heart Journal·Justin A Ezekowitz, Finlay A McAlister
Feb 26, 2009·Archives of Gynecology and Obstetrics·Gabriel de ArribaMaria Angeles Basterrechea
Mar 6, 2009·Clinical Journal of the American Society of Nephrology : CJASN·Sankar D NavaneethanGiovanni F M Strippoli
Oct 22, 2009·JAMA : the Journal of the American Medical Association·Nancy M AlbertGregg C Fonarow
Nov 16, 2010·The New England Journal of Medicine·Faiez ZannadUNKNOWN EMPHASIS-HF Study Group
Feb 24, 2011·Nephrology·Adam MortonAdam Bush
Sep 8, 2011·The Journal of Clinical Hypertension·Murray Epstein, David A Calhoun
Dec 8, 2011·Hypertension·Aderville CabassiAlberto Bacchi-Modena
Jan 12, 2012·JAMA : the Journal of the American Medical Association·Abhinav GoyalMikhail Kosiborod
Aug 7, 2012·Expert Opinion on Drug Safety·Fnu Deepinder, Glenn D Braunstein
Nov 10, 2012·Journal of the American College of Cardiology·Andrew N RassiDeepak L Bhatt
Mar 22, 2013·The American Journal of the Medical Sciences·Mahdi KamounMohamed Abid
Apr 11, 2014·The New England Journal of Medicine·Bertram PittUNKNOWN TOPCAT Investigators
May 9, 2014·Circulation. Heart Failure·Orly VardenyUNKNOWN Randomized Aldactone Evaluation Study (RALES) Investigators
Jun 18, 2015·Current Opinion in Nephrology and Hypertension·Peter KolkhofFrank Eitner
Sep 2, 2015·JAMA : the Journal of the American Medical Association·George L BakrisUNKNOWN Mineralocorticoid Receptor Antagonist Tolerability Study–Diabetic Nephropathy (ARTS-DN) Study Group
Feb 9, 2017·Current Pharmaceutical Design·Charles FaselisPeter Kokkinos

❮ Previous
Next ❯

Citations

Jan 1, 2018·Current Pharmaceutical Design·Konstantinos V StavropoulosCharles J Faselis
Dec 4, 2020·Pharmacological Research : the Official Journal of the Italian Pharmacological Society·Livia LenziniGian Paolo Rossi
Aug 10, 2021·Expert Opinion on Therapeutic Patents·Jun WuXuefei Tan

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.

Related Papers

Current Opinion in Investigational Drugs
Bradley A Maron, Jane A Leopold
Canadian Family Physician Médecin De Famille Canadien
Lisa DolovichKevin Pottie
Hypertension Research : Official Journal of the Japanese Society of Hypertension
Yoshiyu Takeda
© 2022 Meta ULC. All rights reserved